Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 539 | 338 | 1,240 | 22,017 | 33,432 |
| Cost of Goods | 33 | -24 | 65 | 737 | 1,297 |
| Gross Profit | 506 | 362 | 1,175 | 21,280 | 32,135 |
| Operating Expenses | 20,060 | 14,786 | 16,945 | 14,735 | 21,718 |
| Operating Income | -19,521 | -14,448 | -15,705 | 7,282 | 10,714 |
| Interest Expense | 316 | 0 | 0 | 0 | 0 |
| Other Income | -400 | -16,387 | 15,705 | -908 | -25 |
| Pre-tax Income | -20,237 | -30,835 | 0 | 6,374 | 10,689 |
| Income Tax | -1 | 54 | -341 | 29 | 313 |
| Net Income Continuous | -20,236 | -14,851 | -15,697 | 6,345 | 10,376 |
| Net Income | $-20,236 | $-14,851 | $-15,697 | $6,345 | $10,376 |
| EPS Basic Total Ops | -0.98 | 0.29 | -0.76 | 0.31 | -0.51 |
| EPS Basic Continuous Ops | -0.98 | -0.73 | -0.76 | 0.31 | 0.51 |
| EPS Diluted Total Ops | -0.98 | -0.67 | -0.76 | 0.29 | 0.47 |
| EPS Diluted Continuous Ops | -0.98 | -0.68 | -0.76 | 0.29 | 0.48 |
| EBITDA(a) | $-19,312 | $-14,292 | $-15,531 | $7,451 | $10,821 |